Abstract
The severe combined immunodeficiency caused by the absence of adenosine deaminase (SCID-ADA) was the first monogenic disorder for which gene therapy was developed. Over 30 patients have been treated worldwide using the current protocols, and most of them have experienced clinical benefit; importantly, in the absence of any vector-related complications. In this document, we review the progress made so far in the development and establishment of gene therapy as an alternative form of treatment for ADA-SCID patients.
Keywords: Immunodeficiency, Adenosine, Deaminase Deficiency, Adenosine deaminase, severe combined immunodeficiency, gene therapy, hematopoietic stem cell, retrovirus, clinical trial
Current Gene Therapy
Title:Gene Therapy for Severe Combined Immunodeficiency due to Adenosine Deaminase Deficiency
Volume: 12 Issue: 1
Author(s): Claudia A. Montiel-Equihua, Adrian J. Thrasher, H. Bobby Gaspar
Affiliation:
Keywords: Immunodeficiency, Adenosine, Deaminase Deficiency, Adenosine deaminase, severe combined immunodeficiency, gene therapy, hematopoietic stem cell, retrovirus, clinical trial
Abstract:
The severe combined immunodeficiency caused by the absence of adenosine deaminase (SCID-ADA) was the first monogenic disorder for which gene therapy was developed. Over 30 patients have been treated worldwide using the current protocols, and most of them have experienced clinical benefit; importantly, in the absence of any vector-related complications. In this document, we review the progress made so far in the development and establishment of gene therapy as an alternative form of treatment for ADA-SCID patients.
Export Options
About this article
Cite this article as:
Claudia A. Montiel-Equihua, Adrian J. Thrasher, H. Bobby Gaspar , Gene Therapy for Severe Combined Immunodeficiency due to Adenosine Deaminase Deficiency, Current Gene Therapy 2012; 12 (1) . https://dx.doi.org/10.2174/156652312799789253
DOI https://dx.doi.org/10.2174/156652312799789253 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Reactive Oxygen Species in Cancer Biology and Anticancer Therapy
Current Medicinal Chemistry Platelet Activity in the Pathophysiology of Inflammatory Bowel Diseases
Current Drug Targets Cytotoxic and Allergenic Potential of Bioactive Proteins and Peptides
Current Pharmaceutical Design Gender Disparity in Pediatric Diseases
Current Molecular Medicine Role of Oxidative Stress in Hepatitis C Virus Induced Hepatocellular Carcinoma
Current Cancer Drug Targets The Link Between CD6 and Autoimmunity: Genetic and Cellular Associations
Current Drug Targets Induced Pluripotent Stem Cells (iPSCs) Derived from Different Cell Sources and their Potential for Regenerative and Personalized Medicine
Current Molecular Medicine Pin1: A New Outlook in Alzheimers Disease
Current Alzheimer Research Role of the Non-Receptor Tyrosine Kinase Fes in Cancer
Current Medicinal Chemistry The Influence of Cox-2 and Bioactive Lipids on Hematological Cancers
Current Angiogenesis (Discontinued) Targeting Cancer Stem Cells with Natural Products
Current Drug Targets Lipid-Based Drug Delivery Systems for Cancer Treatment
Current Drug Targets Ceramide and Apoptosis: Exploring the Enigmatic Connections between Sphingolipid Metabolism and Programmed Cell Death
Anti-Cancer Agents in Medicinal Chemistry Antiangiogenesis in Myelodysplastic Syndrome
Current Cancer Drug Targets Targeting Cancer Stem Cell Lines as a New Treatment of Human Cancer
Recent Patents on Anti-Cancer Drug Discovery T Cell Tuning for Tumour Therapy: Enhancing Effector Function and Memory Potential of Therapeutic T cells
Current Gene Therapy Therapeutic Potential of Adipose-derived Stem Cells in the Treatment of Pulmonary Diseases
Current Stem Cell Research & Therapy Advances in the Management of Brain Tumors in Infants
Current Cancer Therapy Reviews Analytical Methods of Bioactive Metabolites Produced by Plants and Microorganisms
Current Pharmaceutical Analysis Chemical Advances in Therapeutic Application of Exosomes and Liposomes
Current Medicinal Chemistry